R7999 matching placebo clinical trials

A Phase 2, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Subcutaneously Administered REGN7999 (An Inhibitor of TMPRSS6) in Participants with Iron Overload Due to Non-Transfusion Dependent β-Thalassemia.

This study is testing a new medicine (REGN7999) for adults with a gentle type of beta-thalassemia (NTDT) and too much iron in their body. It aims to see if the medicine can reduce iron levels and improve health, compared to a placebo, with minimal side effects.